SCN4A encodes Nav1.4, the principal voltage-gated sodium channel alpha subunit expressed predominantly in skeletal muscle. It is a canonical excitability gene with well-established disease associations in periodic paralysis and nondystrophic myotonia[1][2][3]. While SCN4A is not classified as a primary neurodegenerative disease gene, its channel biology provides important insights into membrane excitability alterations observed in amyotrophic lateral sclerosis, Parkinson's disease, and related neuromuscular complications of neurodegeneration[4][5].
| Property | Value |
|---|---|
| Gene Symbol | SCN4A |
| Full Name | Sodium Voltage-Gated Channel Alpha Subunit 4 |
| Chromosomal Location | 17q23.3 |
| NCBI Gene ID | 6328 |
| Ensembl ID | ENSG00000007314 |
| UniProt | Q9UQD0 (Nav1.4) |
| Protein Class | Voltage-gated sodium channel (Nav channel) |
Nav1.4 is a large transmembrane protein comprising four homologous domains (I-IV), each containing six transmembrane segments (S1-S6)[1:1][2:1]. The S4 segments in each domain serve as voltage sensors, containing positively charged arginine and lysine residues that move outward upon depolarization to initiate channel activation[2:2][3:1]. The pore-forming region is formed by the S5-S6 segments, which create the selective filter allowing sodium ions to pass through the membrane[1:2][2:3].
Key structural features:
The sodium current (INa) through Nav1.4 exhibits complex gating behavior essential for muscle excitability[2:5][3:3]:
Mutations affecting these gating processes produce the channelopathies associated with SCN4A[2:6][3:5][5:1].
Gain-of-function mutations in SCN4A cause hyperkalemic periodic paralysis by producing persistent inward sodium current that depolarizes the muscle membrane, leading to weakness[3:6][5:2]. The depolarization inactivates normal sodium channels, rendering muscle fibers inexcitable during attacks[3:7].
Key features:
While primarily caused by CACNA1S mutations, certain SCN4A variants can produce HypoKPP phenotypes[3:8][5:4]. These mutations stabilize the channel in a leaky state that is sensitive to membrane depolarization by hypokalemia[3:9].
Caused by mutations that impair channel inactivation, leading to myotonia (muscle stiffness) that paradoxically worsens with continued exercise (paradoxical myotonia)[2:7][5:5].
Mutations causing gain-of-function without significant paralysis produce myotonia without periodic paralysis[2:8][5:6].
While SCN4A is primarily expressed in skeletal muscle, research has revealed important connections to neurodegenerative [4:1][5:7][6]:
Sodium channel dysfunction contributes to excitotoxicity through several [4:6][6:2]:
Sodium channels are therapeutic targets in neurodegeneration[4:8][6:4]:
Over 200 pathogenic variants in SCN4A have been described[2:9][3:10][5:14]:
| Variant Type | Effect | Associated Phenotype |
|---|---|---|
| Missense | Gain-of-function | HyperKPP, Paramyotonia |
| Missense | Loss-of-function | HypoKPP |
| Missense | Mixed | Myotonia fluctuans |
Specific amino acid residues correlate with clinical phenotypes[2:10][3:11]:
When evaluating patients with weakness in the context of suspected neurodegenerative disease, clinicians must consider SCN4A channelopathies as differential diagnoses[4:10][5:18][6:6]:
| Feature | SCN4A Channelopathy | ALS | PD |
|---|---|---|---|
| Onset | Childhood/adolescence | Adult | Adult |
| Attack patterns | Episodic weakness | Progressive weakness | Gradual progression |
| CK levels | Normal to elevated | Normal | Normal |
| EMG | Myotonic discharges | Neurogenic changes | Normal |
Different SCN4A mutations confer varying drug responses[2:13][5:20][6:7]:
Current research areas include[2:15][3:12][4:13][6:9]:
Mouse models carrying SCN4A mutations recapitulate human channelopathy phenotypes[3:14][5:23]:
Cannon SC. Sodium channelopathies of skeletal muscle. Handb Clin Neurol. 2018. ↩︎ ↩︎ ↩︎
Ptacek LJ, Fu YH. Channelopathies: ion channel disorders of muscle. Neurol Clin. 2000. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Cannon SC. Targeting sodium channels in muscle disorders. Nat Rev Drug Discov. 2010. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Waerman S, et al. Motor neuron hyperexcitability in ALS: role of ion channels. J Neurol Sci. 2020. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Finsterer J. Primary periodic paralyses: diagnosis and management. Neurologist. 2019. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Van den Bosch L, et al. Sodium channels as therapeutic targets in amyotrophic lateral sclerosis. Expert Opin Ther Targets. 2010. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎